Sierra Oncology Inc (OQ:SRRA)

Business Focus: Bio Therapeutic Drugs

Recent Price for SRRA
USD 1.570 +0.160 (+11.348%)
NASDAQ Delayed 15 minutes
10:03 EST
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
1.600 8.240 N/A 655,317 78.27
1-Day Low 52-Week Low Yield Avg. Volume  
1.500 1.310 0.0% 281,253  
Feb 09, 2017 09:11 ET
Sierra Oncology Announces Pricing of Public Offering of Common Stock
VANCOUVER, Feb. 9, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price of $1.35 per share, with expected gross proceeds to Sierra Oncology of $26.3 million. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,925,000 additional shares of common stock at the public offering price, less u...
Feb 09, 2017 09:11 ET
Sierra Oncology Announces Pricing of Public Offering of Common Stock
VANCOUVER, Feb. 9, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price of $1.35 per share, with expected gross proceeds to Sierra Oncology of $26.3 million. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,925,000 additional shares of common stock at the public offering price,...
Feb 08, 2017 16:01 ET
Sierra Oncology Announces Proposed Public Offering of Common Stock
VANCOUVER, Feb. 8, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Sierra Oncology. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to ...
Feb 08, 2017 16:01 ET
Sierra Oncology Announces Proposed Public Offering of Common Stock
VANCOUVER, Feb. 8, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Sierra Oncology. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or...